Does informing people about their genetic risk of obesity help them change their habits and lose excess weight? A study, published in the journal Obesity Reviews by scientists including researchers… read more.
Novo Nordisk announced that the European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI… read more.
More people are living with severe obesity, and weight-loss medication is being used widely. But what does that mean for overall health beyond weight loss? A new study… read more.
Medicare prescriptions for Wegovy increased sharply after the program started covering the anti-obesity medication to prevent heart problems, but just a fraction of beneficiaries likely eligible received the… read more.
Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life and few show cardiovascular benefits at one year, finds… read more.
A new “secret shopper” study published in JAMA has raised concerns about the oversight of online vendors prescribing glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the popular class of… read more.
This study is the first to analyse obesity trends from 2019 to 2025, using NHS England electronic health records covering nearly 55 million adults. The scale and detail… read more.
Adolescents with obesity achieve the greatest short-term weight reduction when obesity management medications are used alongside lifestyle treatment, according to a systematic review and network meta-analysis published in… read more.
Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome… read more.
A new study from Michigan State University found increases in binge eating when taking hormone pills in the form of oral contraceptives — but not in all women…. read more.
A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate substantially increased risk for nonlive… read more.
People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society’s annual meeting… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
